Artesunate in combination with oxacillin protect sepsis model mice challenged with lethal live methicillin-resistant Staphylococcus aureus (MRSA) via its inhibition on proinflammatory cytokines release and enhancement on antibacterial activity of oxacillin.

摘要

Sepsis induced by methicillin-resistant Staphylococcus aureus (MRSA) has worse outcome because of multiresistance to a large group of antibiotics, which may lead to death from septic shock. In the present study, we firstly found that artesunate in combination with oxacillin was capable of protecting mice challenged with live MRSA WHO-2 (WHO-2) and the protection was related to the reduced TNF-alpha and IL-6 levels and decreased bacterial load. Based on above results, artesunate was further investigated from two aspects in vitro, anti-inflammation effect and antibacterial enhancement effect on antibiotics. Artesunate not only inhibited TNF-alpha and IL-6 release but also inhibited mRNA and protein expressions of TLR2 and Nod2, two important receptors, in murine peritoneal macrophages stimulated with heat-killed WHO-2, further demonstrating anti-inflammatory effect of artesunate was related to the inhibition of TLR2- and Nod2-mediated proinflammatory cytokines. Significantly, artesunate enhanced antibacterial activity of oxacillin and ampicillin not levofloxacin against WHO-2 and a clinical MRSA strain; the fractional inhibitory concentration indexes were lower than 0.5. Further, artesunate possessed moderate affinity for penicillin-binding protein 2a (PBP2a) and reduced the mecA mRNA expression up-regulated by oxacillin, suggesting that artesunate's enhancement on antibacterial activity of beta-lactams was related to the inhibition of PBP2a and down-regulation of mecA mRNA expression. In conclusion, our results demonstrated that artesunate in combination with oxacillin protected mice challenged with lethal live MRSA via its inhibition on proinflammatory cytokines release and enhancement on antibacterial activity of oxacillin. Artesunate could be further investigated as a candidate drug for MRSA sepsis.